Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clini… Read more
Shuttle Pharmaceuticals Inc (SHPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.884x
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has a cash flow conversion efficiency ratio of -1.884x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.63 Million) by net assets ($1.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shuttle Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Shuttle Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shuttle Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sirona Biochem Corp
PINK:SRBCF
|
0.160x |
|
Inca Minerals Ltd
AU:ICG
|
-0.045x |
|
Tower One Wireless Corp
STU:1P3N
|
-0.544x |
|
Tokyo Plast International Limited
NSE:TOKYOPLAST
|
-0.028x |
|
Kula Gold Ltd
AU:KGD
|
-0.204x |
|
Damodar Industries Limited
NSE:DAMODARIND
|
0.146x |
|
Diagnamed Holdings Corp.
PINK:DGNMF
|
0.150x |
|
ARCUS DEVELOPMENT
MU:AJR
|
0.000x |
Annual Cash Flow Conversion Efficiency for Shuttle Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Shuttle Pharmaceuticals Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $709.15K | $-7.33 Million | -10.332x | -650.85% |
| 2023-12-31 | $4.06 Million | $-5.58 Million | -1.376x | -289.81% |
| 2022-12-31 | $7.68 Million | $-2.71 Million | -0.353x | -291.37% |
| 2021-12-31 | $-1.63 Million | $-300.34K | 0.184x | +1062.10% |
| 2020-12-31 | $-1.69 Million | $-26.83K | 0.016x | +100.08% |
| 2018-12-31 | $27.46K | $-566.69K | -20.640x | -2995.31% |
| 2017-12-31 | $-284.35K | $-202.71K | 0.713x | -- |